A hierarchical rank test for crossover trials with censored data

被引:2
|
作者
Brittain, Erica [1 ]
Follmann, Dean [1 ]
机构
[1] NIAID, Biostat Res Branch, Bethesda, MD 20892 USA
关键词
crossover trials; Cox regression; subjective rankings; survival times; SUBJECTIVE RANKINGS; CLINICAL-TRIALS;
D O I
10.1002/sim.4398
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
We propose an approach to analyze survival time in a crossover clinical trial by performing a primary ranking on whether events occur and a secondary ranking on event times. This hierarchical ranking method is meant to reflect the idea that the goal of therapy is to prevent a clinical event and, failing that, to delay the occurrence of the event, hopefully for a substantial amount of time. We compare our approach with other methods including one method proposed by Feingold and Gillespie, a recommended procedure. The power is similar in many settings, but the hierarchical ranking can have substantially greater power under certain censoring patterns and also under a cure model, or models where treatment induces a substantial delay in some fraction of patients. We additionally feel that the hierarchical ranking method should be more clinically relevant in many settings. The method can also be applied to continuous outcomes censored by a limit of detection, such as HIV viremia. Copyright (C) 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:3507 / 3519
页数:13
相关论文
共 50 条
  • [31] Cost-effectiveness analysis using data from multinational trials: The use of bivariate hierarchical modeling
    Manca, Andrea
    Lambert, Paul C.
    Sculpher, Mark
    Rice, Nigel
    MEDICAL DECISION MAKING, 2007, 27 (04) : 471 - 490
  • [32] Bayesian Hierarchical Models for Cost-Effectiveness Analyses that Use Data from Cluster Randomized Trials
    Grieve, Richard
    Nixon, Richard
    Thompson, Simon G.
    MEDICAL DECISION MAKING, 2010, 30 (02) : 163 - 175
  • [33] Identification of influential observations in high-dimensional cancer survival data through the rank product test
    Carrasquinha, Eunice
    Verissimo, Andre
    Lopes, Marta B.
    Vinga, Susana
    BIODATA MINING, 2018, 11
  • [34] INCREASING POWER IN RANDOMIZED TRIALS WITH RIGHT CENSORED OUTCOMES THROUGH COVARIATE ADJUSTMENT
    Moore, K. L.
    van der Laan, M. J.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2009, 19 (06) : 1099 - 1131
  • [35] REGRESSION FOR CENSORED SURVIVAL-DATA WITH LAG EFFECTS
    LUO, XL
    TURNBULL, BW
    CAI, HY
    CLARK, LC
    COMMUNICATIONS IN STATISTICS-THEORY AND METHODS, 1994, 23 (12) : 3417 - 3438
  • [36] Unbiased and efficient estimation of causal treatment effects in crossover trials
    Madsen, Jeppe Ekstrand Halkjaer
    Scheike, Thomas
    Pipper, Christian
    BIOMETRICAL JOURNAL, 2023, 65 (08)
  • [37] Registration of phase 3 crossover trials on ClinicalTrials.gov
    Lijuan Zeng
    Riaz Qureshi
    Shilpa Viswanathan
    Lea Drye
    Tianjing Li
    Trials, 21
  • [38] Estimating the survival functions for right-censored and interval-censored data with piecewise constant hazard functions
    He, Pei
    Kong, George
    Su, Zheng
    CONTEMPORARY CLINICAL TRIALS, 2013, 35 (02) : 122 - 127
  • [39] Exploratory data analysis of irregular patterns of longitudinal laboratory data from clinical trials - A case study of liver function test
    Lee, KR
    Lydick, E
    Park, DC
    MEDINFO 2001: PROCEEDINGS OF THE 10TH WORLD CONGRESS ON MEDICAL INFORMATICS, PTS 1 AND 2, 2001, 84 : 873 - 873
  • [40] Power Piecewise Exponential Model for Interval-Censored Data
    dos Santos Junior, Paulo Cerqueira
    Schneider, Silvana
    JOURNAL OF STATISTICAL THEORY AND PRACTICE, 2022, 16 (02)